Literature DB >> 22536988

ACR Appropriateness Criteria® non-spine bone metastases.

Stephen T Lutz, Simon Shek-Man Lo, Eric L Chang, Nicholas Galanopoulos, David D Howell, Edward Y Kim, Andre A Konski, Neeta D Pandit-Taskar, Samuel Ryu, Larry N Silverman, Catherine Van Poznak, Kristy L Weber.   

Abstract

Bone is one of the most common sites of metastatic spread of malignancy, with possible deleterious effects including pain, hypercalcemia, and pathologic fracture. External beam radiotherapy (EBRT) remains the mainstay for treatment of painful bone metastases. EBRT may be combined with other local therapies like surgery or with systemic treatments like chemotherapy, hormonal therapy, osteoclast inhibitors, or radiopharmaceuticals. EBRT is not commonly recommended for patients with asymptomatic bone metastases unless they are associated with a risk of pathologic fracture. For those who do receive EBRT, appropriate fractionation schemes include 30 Gy in 10 fractions, 24 Gy in 6 fractions, 20 Gy in 5 fractions, or a single 8 Gy fraction. Single fraction treatment maximizes convenience, while fractionated treatment courses are associated with a lower incidence of retreatment. The appropriate postoperative dose fractionation following surgical stabilization is uncertain. Reirradiation with EBRT may be safe and provide pain relief, though retreatment might create side effect risks which warrant its use as part of a clinical trial. All patients with bone metastases should be considered for concurrent management by a palliative care team, with patients whose life expectancy is less than six months appropriate for hospice evaluation. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every two years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.

Entities:  

Mesh:

Year:  2012        PMID: 22536988     DOI: 10.1089/jpm.2011.0512

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


  7 in total

1.  Doing palliative care in the oncology office.

Authors:  M Jennifer Cheng; Lauren M King; Erin R Alesi; Thomas J Smith
Journal:  J Oncol Pract       Date:  2013-03       Impact factor: 3.840

2.  Persistent Use of Extended Fractionation Palliative Radiotherapy for Medicare Beneficiaries With Metastatic Breast Cancer, 2011 to 2014.

Authors:  James B Yu; Craig E Pollack; Jeph Herrin; Weiwei Zhu; Pamela R Soulos; Xiao Xu; Cary P Gross
Journal:  Am J Clin Oncol       Date:  2019-06       Impact factor: 2.339

3.  Outcomes and toxicities of stereotactic body radiation therapy for non-spine bone oligometastases.

Authors:  Dawn Owen; Nadia N Laack; Charles S Mayo; Yolanda I Garces; Sean S Park; Heather J Bauer; Kathryn Nelson; Robert W Miller; Paul D Brown; Kenneth R Olivier
Journal:  Pract Radiat Oncol       Date:  2013-06-29

4.  Stereotactic radiotherapy using the CyberKnife is effective for local control of bone metastases from differentiated thyroid cancer.

Authors:  Takayuki Ishigaki; Takashi Uruno; Kiminori Sugino; Chie Masaki; Junko Akaishi; Kiyomi Y Hames; Akifumi Suzuki; Chisato Tomoda; Kenichi Matsuzu; Keiko Ohkuwa; Wataru Kitagawa; Mitsuji Nagahama; Shinichiro Miyazaki; Koichi Ito
Journal:  J Radiat Res       Date:  2019-11-22       Impact factor: 2.724

5.  Practice patterns for postoperative radiation therapy in patients with metastases to the long bones: a survey of the Japanese Radiation Oncology Study Group.

Authors:  Hikaru Kubota; Naoki Nakamura; Naoto Shikama; Ayako Tonari; Hitoshi Wada; Hideyuki Harada; Hisayasu Nagakura; Joichi Heianna; Kei Ito; Miwako Nozaki; Masao Tago; Masato Fushiki; Nobue Uchida; Norio Araki; Shuhei Sekii; Takashi Kosugi; Takeo Takahashi; Terufumi Kawamoto; Tetsuo Saito; Kazunari Yamada
Journal:  J Radiat Res       Date:  2021-03-10       Impact factor: 2.724

6.  Continuous controversy about radiation oncologists' choice of treatment regimens for bone metastases: should we blame doctors, cancer-related features, or design of previous clinical studies?

Authors:  Carsten Nieder; Adam Pawinski; Astrid Dalhaug
Journal:  Radiat Oncol       Date:  2013-04-10       Impact factor: 3.481

7.  A definition of "uncomplicated bone metastases" based on previous bone metastases radiation trials comparing single-fraction and multi-fraction radiation therapy.

Authors:  Paul M Cheon; Erin Wong; Nemica Thavarajah; Kristopher Dennis; Stephen Lutz; Liang Zeng; Edward Chow
Journal:  J Bone Oncol       Date:  2015-01-23       Impact factor: 4.072

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.